Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).

摘要: Several high-performance liquid chromatographic assays have been reported for the analysis of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in biologic matrices. The recently developed method using solid-phase extraction as a sample pretreatment is preferred, it most sensitive assay and also capable detecting metabolites plasma treated patients. pharmacokinetics NJ), administered different doses schedules, has studied this method. After cessation infusion, three-phasic decay concentrations found. There are indications nonlinear when short infusion at higher doses. Different metabolic products detected Three hydroxylated identified so far. Pharmacokinetics related with pharmacodynamics. Neuropathy, mucositis, leukopenia correlate pharmacokinetic parameters such area under concentration time curve steady-state levels. hematologic toxicity modelled sigmoidal maximum effect equation spent above biologically active threshold 0.1 mumol/L parameters.